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Abstract
Objective. To assess the use of antihypertensive drugs and blood pressure (BP) levels in relation to current guidelines for BP
control in patients with chronic renal failure (CRF). Material and methods. A cross-sectional survey was carried out in six
renal outpatient clinics in Oslo and the surrounding area. The hospital records of all renal patients not yet in need of renal
replacement therapy and with serum creatinine ]/200 mmol/l who attended consultations with nephrologists regularly (at
least every third month) were reviewed. Results. Of the 351 patients, 97% had hypertension. The majority of patients (96%)
were receiving antihypertensive therapy. The average number of antihypertensive drugs being taken was 2.79/ 1.3 (median
3), but it varied with the cause of CRF. The drugs most frequently prescribed as monotherapy were angiotensin-converting
enzyme inhibitors or angiotensin II receptor antagonists, which were used by 32%; 51% of patients were using three or
more antihypertensive drugs. Loop diuretics were prescribed as monotherapy in 25% of cases and in combination with
two or more other drugs in 87%. Age and serum creatinine levels influenced the choice of antihypertensive therapy.
The target BP of B/130/80 mmHg was obtained in 13% of patients, and lack of optimal BP control was mainly due to
systolic hypertension. A total of 38% of patients had a BP of B/140/90 mmHg, while 58% failed to achieve a systolic BP
of B/140 mmHg. Conclusion. Optimal blood pressure control is hard to achieve in patients with CRF, even with specialist
care and the use of multiple antihypertensive drugs.
Key Words: Angiotensin-converting enzyme inhibitors, blood pressure control, chronic renal failure, hypertension, loop
diuretics
Introduction
Hypertension is the single most important risk factor
for progression of diabetic and non-diabetic kidney
disease and renal insufficiency [1"/3]. Lowering
blood pressure per se leads to organ protection,
and medication interfering with the renin"/angioten-
sin system, i.e. angiotensin II receptor antagonists
(ARBs) and angiotensin-converting enzyme inhibi-
tors (ACEIs), confers renoprotection beyond that of
blood pressure lowering [4"/8].
Death from cardiovascular disease in patients with
chronic renal failure (CRF) is high and greatly
exceeds that of the general population [9,10]. It
has thus been argued that risk reduction should start
during the early stages of renal insufficiency [11]. In
high-risk patients, modulation of risk factors, even
within what is considered the normal range, may
have a great impact on cardiovascular morbidity and
mortality [11,12].
Given the benefit of reduction of blood pressure
(BP) in this population, there is consensus regarding
the importance of good control of BP in patients
with chronic kidney disease and renal insuffici-
ency. Thus, recent guidelines based on observational
data [13"/15] advise lowering BP below 130/
80 mmHg.
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Given this background, the aim of this investiga-
tion was to assess the use of antihypertensive drugs
and BP levels in patients with CRF who had not
reached the stage of requiring renal replacement
therapy, but were receiving regular care at renal
units.
Material and methods
Study design
Renal units at six different hospitals in the southern
part of Norway participated in a cross-sectional
survey based on hospital records of patients with
CRF with serum creatinine ]/200 mmol/l. These
hospitals cover the referral area for nephrology for
#/1.75 million Norwegians, close to 40% of the
entire population. The doctors who care for these
patients are all highly trained nephrology specialists.
During a 6-month period, two of the authors (M. G.
S. and L. K. P.) reviewed the hospital records of
patients who had been indicated as eligible for the
study by consulting nephrologists. Only ambulatory
patients could be included, and they had to attend
regular consultations at least every third month at
the renal unit. Furthermore, they had to have
attended a consultation within the previous 3"/4
months. Patients with acute renal failure with serum
creatinine elevation of B/3 months duration, or
patients who had previously been dialyzed or trans-
planted could not be included. Current dialysis was
also an exclusion criterion. All patients who fulfilled
the inclusion criteria were included in the study.
Data from the last visit (within the previous
3 months) were always used. The date of first
admission, diagnosis, cardiovascular history (macro-
vascular disease, i.e. myocardial infarction, stroke,
peripheral vascular disease or aortic aneurysm) and
laboratory measurements at different times (includ-
ing the last visit) were recorded. The drug regimen
in use at the last visit before the survey was used for
registration. The classes of antihypertensive medica-
tion were registered, and for loop diuretics the
dosage was also registered. For those using bumeta-
nide (B/5% of patients), the dose was converted to
that for furosemide, i.e. 1 mg of bumetanide%/40 mg
of furosemide. BP measurements at the time of
admission to hospital and at the last visit before the
present investigation were also entered into the
database. Pulse pressure (PP) was calculated by
subtracting diastolic (D)BP from systolic (S)BP.
The most recent measurements of total cholesterol,
high-density lipoprotein (HDL) cholesterol, trigly-
cerides and glucose available in the hospital records
were noted. Serum creatinine was used as a measure
of kidney function. Creatinine clearance could be
calculated in two-thirds of the patients using the
Cockcroft"/Gault formula. Records of proteinuria
were often lacking and, if they were present, had
been obtained using various methodologies and the
results were mostly qualitative or semi-quantitative.
Therefore these data were not collected.
The diagnosis of diabetic nephropathy was based
on hospital records, as were the other causes of CRF.
In the majority of patients the diagnosis is made on
the basis of clinical assessments, and only in a
minority of cases is it based on renal biopsy. The
cause of CRF was categorized as either chronic
glomerulonephritis, diabetic nephropathy (types 1
and 2), nephrosclerosis and hypertensive renal dis-
ease, chronic pyelonephritis and interstitial nephritis,
or other (renal amyloidosis, adult polycystic kidney
disease and renal carcinoma, unclassified chronic
renal disease).
Patients were labelled as hypertensive based on
hospital records of BP measurements at admission,
use of antihypertensive drugs or a BP at the last visit
of #/140/90 mmHg. Controlled and uncontrolled
hypertension were defined as a BP of B/ and ]/130/
80 mmHg, respectively at the last consultation.
The threshold for defining controlled hypertension
was also set at B/140/90 mmHg, and analysed
accordingly.
Statistics
All data are presented as mean9/ SD unless stated
otherwise. For differences in BP, 95% CIs are given
as well. For skewed data, the median, Q1 (25%
percentile) and Q3 (75% percentile) are given.
Comparisons were made using the x2 test, Student’s
t-test, ANOVA and, for skewed distributions of data,
Wilcoxon’s test and the Mann"/Whitney U-test.
Simple bivariate relationships were assessed by
calculating Spearman’s correlation coefficient. Age
and serum creatinine were also categorized in
tertiles. The statistical analysis was performed using
SPSS statistical software (version 11.0; SPSS Inc.,
Cary, NC). Two-tailed p-values 5/0.05 were con-
sidered statistically significant.
Results
More than 600 hospital records were assessed, and
those of 376 Caucasian patients with CRF who were
not on dialysis and had never previously been
transplanted or dialysed were entered into the
database. Of these, 25 did not fulfil the inclusion
criterion of serum creatinine ]/200 mmol/l at the last
visit, and thus data from 351 patients were analyzed.
The mean time from the first referral for chronic
kidney disease was 40 months, with a wide range of
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3"/394 months. Some of the patient characteristics
are given in Tables I and II (patients are categorized
according to age tertiles in the latter). Age was
positively related, although weakly, to SBP (r%/0. 23,
pB/0.001) and PP (r%/0.25, pB/0.0001), while
an inverse relationship with DBP was observed
(r%/$/0.14, p%/0.003). Serum creatinine did not
differ across the age tertiles at the time of investiga-
tion, while estimated creatinine clearance (n%/223)
showed an inverse relationship with age (r%/$/0.40,
pB/0.001).
The major cause of CRF in this population of
patients attending a renal unit regularly was nephro-
sclerosis, followed by diabetic nephropathy (Table
III). The aetiology of CRF differed with age, with
nephrosclerosis being the most prevalent cause in the
oldest age group and chronic glomerulonephritis
being most frequent in the younger population
(Table III). Diabetes nephropathy as a cause of renal
failure did not differ significantly across the age
tertiles. The presence of macrovascular disease
increased across the age tertiles (Table II).
Use of drugs
Multipharmacy was frequent, with a median of three
drugs (2.79/1.3) being prescribed, while only 3.9%
of patients were not prescribed any antihypertensive
therapy. Overall, the most frequently used drugs
were loop diuretics, which were used by 65.8% of
patients, with an average dose of 1259/124 mg
(median 80 mg; Q1"/Q3 40"/160 mg). Calcium
channel blockers (CCBs) were used by 60.2% of
patients, beta-adrenergic receptor blockers (BBs) by
52.8% and ACEIs or ARBs by 45.1%. Other drugs,
i.e. alpha-receptor blockers, alphamethyldopa, thia-
zides or moxonidine, were used by 39.0%. ACEIs or
ARBs were most frequently used as monotherapy,
while loop diuretics were used as monotherapy by
25% of patients (Table IV). None of the patients in
the current survey used a combination of ACEIs and
ARBs.
The use of medication seemed to differ across the
range of serum creatinine levels, with a significant
decrease in the use of ACEIs and ARBs with rising
creatinine levels, while the use of CCBs and diuretics
remained the same (Figure 1). Loop diuretics were
the most frequently used drugs in the oldest age
groups (p%/0.07). The dosage of loop diuretics also
seemed to be higher in the oldest patients, but this
did not reach statistical significance (p%/0.27).
There was a marked decrease in the use of ACEIs
or ARBs with increasing age (pB/0.0001), with less
than a quarter of the oldest patients using these
classes of drugs. BBs were also more frequently used
in the oldest patients (p%/0.006). Overall use of
statins was 48.3%, and did not differ between age
groups (p%/0.77). The cause of CRF influenced the
use of antihypertensive drugs (Figure 2), and this
was not explained by differences in SBP (p%/0.16),
DBP (p%/0.35) or serum creatinine (p%/0.58).
BP levels
Overall, there was a highly significant decrease in BP
in the hypertensive patients after referral to hospital
(Figure 3). The decrease in SBP was 13.99/27.2,
95% CI 10.9"/16.9 mmHg (pB/0.001), in DBP
7.79/16.4, 5.6"/9.5 mmHg (pB/0.001) and in PP
6.29/ 19.8, 4.0"/8.4 mmHg (pB/0.001).
Only 13% of patients had BP levelsB/130/80
mmHg, and fewer patients obtained a decrease
in SBP compared to DBP (18% vs 34%). The
proportion of patients achieving a BP of B/140/
90 mmHg was 38%, but systolic hypertension (SBP
]/140 mmHg) was still prevalent (58%), while a
DBP of 5/90 mmHg was observed in 75% of cases.
Systolic hypertension was more frequent in older
patients (p%/0.003).
The PP was significantly lower in patients with a
BP of B/130/80 mmHg than in those with uncon-
trolled BP (43.59/8.4 vs 66.99/17.0 mmHg; p%/
0.0001). Furthermore, PP differed depending on
Table I. Charateristics of the study population (n%/351). Unless
stated otherwise, data are presented as mean (SD).
Characteristics Value
Age (years) 63.0 (15.9)
Females (%) 27.9
Hypertension (%) 96.6
Macrovascular disease (%) 37.6
Coronary heart disease (%) 29.6
SBP2
a
(mmHg) 155.7 (25.6)
SBP2
b
(mmHg) 142.6 (21.0)
DBP2
a
(mmHg) 87.6 (16.1)
DBP2
b
(mmHg) 80.4 (10.9)
PP2
a
(mmHg) 68.1 (19.8)
PP2
b
(mmHg) 62.0 (15.9)
Serum creatinine2
a
(mmol/l) 269 (162)
Serum creatinine2
b
(mmol/l) 338 (133)
Creatinine clearance2
b
(ml/min)* 24.7 (11.8)
Serum carbamide2
b
(mmol/l) 20.4 (6.7)
Haemoglobin2
b
(g/dl) 12.2 (1.6)
Base excess (mmol/l) $/2.7 (3.7)
Phosphate (mmol/l) 1.5 (0.4)
Alkaline phosphatase (U/l) 169 (105)
Total cholesterol (mmol/l) 5.2 (1.2)
HDL cholesterol (mmol/l) 1.2 (0.4)
Triglycerides (mmol/l) 2.2 (1.4)
Glucose (mmol/l) 6.3 (2.6)
aAt referral.
bAt the time of the present investigation.
cCalculated using the Cockcroft"/Gault formula, corrected for
gender.
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whether SBP but not DBP was controlled. PP
was significantly lower in patients with an SBP of
B/130 mmHg than in those with an SBP of
]/130 mmHg (48.59/10.8 vs 64.89/ 18.2 mmHg;
pB/0.001). There was no difference in PP in those
with a DBP of B/80 mmHg (64.39/18.7 vs 61.69/
18.1 mmHg; p%/0.19).
The median change in serum creatinine levels for
all patients from the time of referral to the time-point
of the survey was#/55 mmol/l ($/4 to#/147 mmol/l).
There was a weak correlation between the change in
serum creatinine level and DBP at the referral time
(r%/0.22, pB/0.001), but there was no correspond-
ing correlation with SBP (r%/0.14, p%/NS).
Those patients who experienced a rise in serum
creatinine level between the time of referral and the
time of the survey had a higher DBP at the time of
referral compared to those with a decrease in
creatinine level (89.49/15.2 vs 81.29/17.2 mmHg;
mean difference 8.29/4.1 mmHg; pB/0.001), but
there was no significant difference in SBP (156.89/
24.7 vs 151.89/28.3 mmHg; p%/NS). No difference
in PP was observed either (67.49/19.2 vs 70.69/
21.0 mmHg; p%/NS).
Discussion
Close to 97% of our patients with CRF had elevated
BP or were being treated with antihypertensive
drugs, comparable with the prevalence of hyperten-
sion observed in a large American study [16].
This was a highly selected group of patients as
they were receiving regular care from nephrologists
but, despite an impressive decrease in BP between
the referral time and the present survey, BP control
was not optimal. Only 13% of patients had BP
levels in accordance with current recommendations
(B/130/80 mmHg), and uncontrolled SBP was the
major cause of failure to meet that target. The
proportion of patients who achieved the more
conservative BP goal of B/140/90 mm Hg was
38%, in accordance with other reports [16"/18].
This figure is an improvement on what has been
achieved among patients with essential hypertension
in general practice [19].
PP has emerged as an important and independent
risk factor for cardiovascular disease [20] and has
recently been put forward as a major determinant of
progression of renal disease and renal insufficiency
[2]. Some authors have therefore suggested that
Table III. Diagnoses of patients with CRF in different age tertiles. Values are presented as percentages.
Age tertile
Diagnosis 1st 2nd 3rd All
Nephrosclerosis 22.9 37.0 51.6 37.4
Diabetic nephropathy 17.8 26.9 19.8 21.3
Chronic glomerulonephritis 27.1 15.7 12.9 18.7
Chronic pyelonephritis/interstitial nephritis 16.9 11.1 8.0 12.0
Others 15.2 9.2 6.8 10.5
Table II. Characteristics of the study population (n%/351) classiﬁed in age tertiles. Unless stated otherwise, data are presented as mean
(SD).
Age tertile
Characteristic 1st 2nd 3rd p
Age (years) 45.7 (10.6) 50.6 (3.8) 78.1 (4.0) B/0.001
Females (%) 31 27 23 0.39
Hypertension (%) 91.2 96.2 96.7 0.16
Macrovascular disease (%) 13.3 44.8 59.5 B/0.001
Time from first referral (months) 45 (50) 50 (67) 27 (33) 0.003
SBP2
b
(mmHg) 138.9 (20.2) 144.9 (18.3) 146.6 (23.3) 0.015
DBP2
b
(mmHg) 83.3 (11.5) 80.9 (9.5) 78.1 (1.0) 0.001
PP2
b
(mmHg) 55.5 (17.1) 63.9 (16.5) 68.5 (19.0) B/0.001
Serum creatinine2
a
(mmol/l) 236 (153) 287 (207) 283 (116) 0.03
Serum creatinine2
b
(mmol/l) 331 (124) 339 (128) 341 (131) 0.828
Serum carbamide2
b
(mmol/l) 19.8 (5.7) 19.9 (6.4) 20.4 (7.7) 0.073
Haemoglobinb (g/dl) 12.3 (1.8) 12.2 (1.4) 12.0 (1.6) 0.18
aAt referral.
bAt the time of the present investigation.
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rather than aiming at good control of DBP, the focus
should be on controlling SBP and PP [2]. In elderly
hypertensive subjects with isolated systolic hyperten-
sion, an increase in PP of 10 mmHg confers in-
creased risks of congestive heart failure and stroke of
32% and 24%, respectively [21].
The number of patients in the present study is too
small to enable definite conclusions to be drawn
regarding differences in the prevalence of hyperten-
sion depending on the aetiology of CRF, as others
have done [16,17]. However, we did note a differ-
ence in the use of antihypertensive drugs depending
on aetiology, as the number of drugs prescribed was
higher in patients with diabetic nephropathy or
nephrosclerosis compared to those with chronic
glomerulonephritis.
Some of the usual barriers to good BP control, e.g.
access to good healthcare, cannot explain our finding
of a low rate of optimal BP control as specialist
hospital care was a prerequisite for entering the
study. The majority of our patients required multiple
antihypertensive drugs: the average number of drugs
prescribed in the present study was higher than that
reported in other studies [17], but similar to that
used in randomized clinical trials [4,6,22]. The
patients in the present survey had more severe renal
impairment than those in comparable studies ad-
dressing BP control, and our patients also suffered
more from macrovascular disease.
Multipharmacy was prevalent, and the majority of
patients used two or more drugs. Drugs interfering
with the renin"/angiotensin system were those most
frequently used as monotherapy, but they were also
prescribed to more than half of patients using three
or more antihypertensive drugs. Overall, loop diure-
tics were the most frequently prescribed antihyper-
tensive drugs. While a quarter of patients receiving
monotherapy used loop diuretics, the proportion
rose to 87% when three or more drugs were
prescribed. Furthermore, a high proportion of pa-
tients used CCBs and BBs. Among younger patients,
ACEIs or ARBs were more often preferred, which
were used in only a minority in the upper age group.
Figure 2. The number of antihypertensive drugs used according
to the aetiology of CRF. CGN%/chronic glomerulonephritis;
DM%/diabetes mellitus; N%/nephrosclerosis/hypertensive renal
disease; IN%/interstitial nephritis/chronic pyelonephritis. Com-
parisons between different groups were made using Wilcoxon’s
test.
Figure 1. Use of different antihypertensive drugs in the different
serum creatinine tertiles in patients with CRF with serum
creatinine levels ]/200 mol/l. Comparisons were made using
one-way ANOVA.
Table IV. Usage (%) of different classes of antihypertensive drugs
given as monotherapy, with one other drug or with two or more
other drugs.
Form of administration
Antihypertensive
As
monotherapy
With one
other drug
With two or more
other drugs
ACEIs/ARBs 32 42 51
CCBs 18 48 83
BBs 13 40 75
Loop diuretics 25 55 87
Others 2 18 65
Figure 3. BP levels and PP at the time of admission to a renal unit
(solid bars ) and at the time of the study (hatched bars ) in patients
with CRF and hypertension (n%/339).
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The use of diuretics increased in the oldest age
group.
The frequent choice of ACEIs or ARBs is not
surprising given the results of recent clinical trials in
both diabetic and non-diabetic kidney disease in-
dicating a renoprotective role of these drugs beyond
that which can be explained by blood pressure
lowering [2,4"/8,22]. Excess volume plays an im-
portant role in developing and sustaining hyperten-
sion in CRF [23] and therefore use of loop diuretics
is frequent, as observed in our study. As the effect of
loop diuretics is dependent on renal function, the
dose should be increased in this patient population,
which may lead to improved BP control. Combina-
tion therapy with ACEIs and ARBs has been
proposed [24"/26], but none of the patients used
this combination in the present survey. As kidney
function declines, the risk of accumulation of ACEIs
increases, and this is probably the major cause for
the decreased usage of ACEIs with advancing renal
failure. However, this could lead to use of these drug
classes being overly restricted in patients who may
benefit from the treatment [27,28].
CCBs are recommended in the form of combina-
tion therapy in renal patients [29]. It has been
proposed [30,31] that CCBs may be particularly
beneficial in patients with end-stage renal failure
with disturbances of calcium"/phosphate metabo-
lism. However, a more likely explanation for the
frequent use of CCBs is their safety profile in this
setting.
Newer data [32,33] suggest that sympathetic
overactivity is an important contributor to hyperten-
sion in renal failure, and renal patients may therefore
benefit from the use of BBs. Furthermore, a
substantial number of patients in the current survey
were suffering from coronary heart disease, which
would have increased the use of BBs.
Based on the strict inclusion criteria we used to
select our patients, our findings may not be applic-
able to patients with creatinine values B/200 mmol/l,
those attending outpatient examinations at regular
intervals of #/3 months or not on a regular basis and
patients attending examinations but with consultants
other than a nephrologist.
A further limitation of this study is that it was
based on data from hospital charts. We have no
information about compliance with or adherence to
the prescribed drug regimens. The BP recordings
were all taken in a sitting position and in accordance
with good clinical practice, and these measurements
were the ones the nephrologists based their decisions
on. In the majority of cases, the cause of CRF is
determined based on clinical assessment rather than
renal biopsy. This may lead to overestimation of the
incidences of nephrosclerosis and diabetic nephro-
pathy. However, the high number of cases of
nephrosclerosis or hypertensive renal disease that
were registered in the present survey is in accordance
with the increase in prevalence observed in other
European countries, and also in agreement with
reports from the Norwegian registry for patients
enrolled in dialysis treatment or transplantation
programmes [34]. Hypertension as a primary cause
of end-stage renal failure has risen from 5% to 28%
over the last 20 years, while chronic glomerulone-
phritis has decreased from 34% to 17% [34].
This study took place in 2003, the same year in
which new guidelines were issued [13"/15]. There
seems to be a consensus regarding the target BP in
patients with nephropathy, despite the fact that the
guidelines are based on observational findings and
there is a paucity of findings from clinical trials.
However, in some studies [35] the renoprotective
effect of a target BP of B/130/80 mmHg, as opposed
to B/140/90 mmHg, is not supported.
In conclusion, although hypertension is the single
most important risk factor for progression of chronic
kidney disease, and a major risk factor for cardio-
vascular disease in renal patients, BP control in this
high-risk population is far from optimal, despite the
extensive use of multiple antihypertensive drugs.
Randomized controlled studies defining the thresh-
old for optimal BP control in patients with CRF are
clearly needed. Based on our observations, we
suggest that a higher dosage of loop diuretics should
be considered to improve BP control in renal
patients, and that the use of drugs interfering with
the renin"/angiotensin system should be carefully
scrutinized in these patients.
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